Summary of the characteristics of the 80 participating studies.

aPercentage of the number given in the total row (percentages for each variable do not always add to 100 because of rounding errors).bIncludes four studies from Morocco (number of women with known ER, PR, and HER2 status: 1,451, 1,451, and 411, respectively), three from Libya (378, 378, 78, respectively), two from Sudan (162, 162, and 114, respectively), and two from Algeria (296, 296, and 296, respectively) (see Tables 1 and 2).cIncludes a multi-centric study [8] with several centres based in Nigeria and one in Senegal (number of women with known ER, PR, and HER2 status: 378, 378, and 378, respectively).dIncludes two studies from Mali (number of women with known ER, PR, and HER2 status: 273, 272, and 113, respectively); four from Ghana (320, 293, and 258, respectively); two from Uganda (296, 183 and 183, respectively), two from Kenya (278, 158 and 192, respectively), two from Tanzania (125, 125 and 0, respectively), and one from Madagascar (75 and 77, respectively) (see Tables 1 and 2).eDefined according to the last year in which patient recruitment took place.fIf information on menopausal status was not available women aged >50 years at diagnosis were classified as postmenopausal.Summary of the characteristics of the 80 participating studies.